-
Not all patients develop HAMA. The development of HAMA can be delayed by several months by administering certain kinds of chemotherapy in high doses prior to initiating treatment. HAMA forces patients to stop treatment with monoclonal antibodies since it neutralizes the antibodies and the disease is...
-
3F8 is a mouse derived monoclonal antibody developed by Dr. Cheung at Case Western Reserve University in the 1980’s, and later tested extensively at Memorial Sloan- Kettering Cancer Center. It is directed toward sugar containing molecules called GD2 found on the surface of neuroblastoma cells....
-
Although the ch14.18 and 3F8 antibodies both share the same target on neuroblastoma cells, the GD2 antigen, there are significant differences between them. The two antibodies differ in structure, in protocol design and availability, in comparisons of study results, and in method of administration. For...
-
Antibody therapy is believed to rely on three different methods to kill neuroblastoma cells. These are called antibody dependent cell-mediated cytotoxicity (ADCC), complement mediated cytotoxicity (CMC), and passive immunotherapy using the anti-idiotypic network. The names sound much scarier that it...
-
One of the great things about being a mouse is the fact that mice do not naturally get neuroblastoma. Mice develop antibodies that attach to neuroblastoma cells thus alerting the immune system to come and kill the tumor cell. Neuroblastoma cells get killed before they even get a chance to turn into tumors...